An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2018
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 26 May 2018 Planned End Date changed from 19 Jan 2022 to 30 Mar 2023.
- 26 May 2018 Planned primary completion date changed from 19 Jan 2022 to 30 Mar 2023.
- 24 Mar 2017 New trial record